Overview
Foghorn Therapeutics Q3 collaboration revenue rises, driven by Lilly partnership
Net loss for Q3 decreases compared to last year
Company maintains strong cash position with runway into 2028
Outlook
Foghorn expects selective CBP degrader to be IND-ready in 2026
Company anticipates IND-enabling studies for EP300 degrader in 2026
Foghorn projects ARID1B degrader in vivo proof of concept in 2026
Result Drivers
LILLY COLLABORATION - Ongoing collaboration with Lilly drives advancement of novel oncology medicines, including FHD-909 program
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Collaboration Revenue
$8.15 mln
Q3 EPS
-$0.25
Q3 Net Income
-$15.84 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Foghorn Therapeutics Inc is $11.50, about 69.3% above its November 4 closing price of $3.53
Press Release: ID:nGNXbvYtKl
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
